Dallas, Texas 01/02/2014 (FINANCIALSTRENDS) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), the 1.27 billion market-cap pharmaceutical which develops therapies with cell signalling with small molecules to treat cancer has since won FDA approval for its leukaemia drug – Iclusig (ponatinib). FDAs Christmas gift comes just-in time for the major pharmaceutical as Iclusig has been a major prospect for the company. FDA approval was possible only after revised USPI and REMS for Iclusig were announced.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA),can following the approval by FDA, resume the marketing as well as commercial distribution of Iclusig.
In October last, Iclusig was suspended when FDA did not allow new patient enrolment for clinical trials, due to the high incidence of toxic in the vessels for PACE trails in patients demonstrating Chronic Myeloid Leukaemia. The initial hold later led to the temporary cessation in sales and marketing of the drug.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) can now market Iclusig but now the drug carries an alert indicative of vascular Occlusive and of heart failure as well. However, Iclusig has been the second-in-line treatment and has found great advocacy amongst physicians and patient advocacy groups, as the drug was found to have shown remission in patients who had otherwise become resistant to other drugs
In fact, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) had worked upon other channels available, such as the Investigational New Drug or IND channels to ensure that patients could be delivered Iclusing. Under the IND channel, the FDA allows the investigation of new drugs on single patients. FDA will however, exercise maximum control, by reviewing on a per-patient basis. Under this channel over 90patients could access this drug. Priced at $115,000 for an year, Iclusig definitely lives up to be one of the most expensive drugs currently available for the treatment of this condition. Now, with the drug being commercially available, patients have new hope!
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.